AIBN National Biologics Facility
directed by David Chin
+61 7 3346 4269
a member since 4/20/2011

Contact Info

For information contact
David Chin or Trent Munro.

+61 7 3346 4269
The University of Queensland
Australian Institute for Bioengineering and Nanotechnology (AIBN)
Building 75 - Cnr of College and Cooper Road
St Lucia, QLD 4072


Services Provided

This facility provides research grade material and offers production support to both Academics and Companies.

Biologics Produced

  • working cell banks
  • recombinant proteins from bacteria and yeast
  • Monoclonal Antibodies
  • Bacteria
  • Activated Pharmaceutical Ingredients

About this facility

About the Biologics Facility

Biologics is an exciting and rapidly expanding class of human therapeutics, developed using advances in biotechnology and genetic engineering. AIBN houses the NCRIS Biologics Facility (NBF), which is the Queensland Node of the NCRIS Biotechnology Products capability. Facility staff have expertise in biopharmaceutical development and production, ranging from academic research to overseas industrial experience, as well as the application of current Good Manufacturing Practice (cGMP).
The NBF provides the infrastructure and biotechnology know-how to enable Australian academic and industrial researchers to bridge the gap between laboratory experiments and production of material for pre-clinical and clinical trials. The NBF is housed in a purpose-built, $13 million facility consisting of laboratories, clean rooms, state-of-the-art equipment and expertise. Staff can advise on and execute all stages of biopharmaceutical pre-clinical development, from the generation of well-characterised cell lines to the design of bioprocesses suitable for large-scale production.
The Facility is currently working with a number of academic research institutes and industry collaborators on the development and production of the next generation of biological therapeutics.

The Facility has high-throughput capabilities for cell line development and clonal isolation. This includes a Fluorescence Activated Cell Sorter (BD FACSAria II) and robotics for rapid isolation of high-producing clones (ClonePixTM FL). This further strengthens our expertise and capabilities in mammalian cell technology.
The NBF is equipped with a variety of bioreactors up to 100L scale, including stirred tank and single-use systems. In addition, the facility contains dedicated processing suites for product recovery and purification.
Finally, the Facility has the capabilities to study the stability of protein therapeutics during storage, transport and use through a combination of calorimetric and spectrometric instruments.

The facility extends its know-how in mammalian cell technology through research into enhancing recombinant protein product in mammalian systems, antibody engineering and characterisation of protein structure and function.